![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Supreme Court Denies On-Sale Bar Appeal from Merck, Bayer
Supreme Court Denies On-Sale Bar Appeal from Merck, Bayer
January 19, 2017
The U.S. Supreme Court denied Merck and Bayer’s appeal of a Federal Circuit ruling that confidential sales trigger the on-sale standard for patent invalidation.
The high court’s denial lets stand the Federal Circuit decision, which overturned a district court ruling that found the company’s secret negotiations to commercialize Metafolin did not invalidate Merck’s patents.
Merck and Bayer filed a petition in October, maintaining that only public sales initiate the on-sale standard.
Upcoming Events
-
21Oct